详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis

39| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]College of Life Science and Technology, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China [2]College of Life Science and Technology, Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin of Xinjiang Production and Construction Corps, Tarim University, Alar 843300, Xinjiang, China [3]College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA [4]Department of Urology, The Afliated Hospital of Hebei University, Baoding 071030, China [5]Department of Urology, China-Japan Friendship Hospital, Beijing 100029, China [6]Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China [7]Department of Urology, The Second Afiated Hospital of Kunming Medical University, Kunming 650101, China

出处：

DOI：

ISSN：

摘要：

Comprehensive investigation of tumor-infiltrating lymphocytes in cancer is crucial to explore the effective immunotherapies, but the composition of infiltrating T cells in urothelial bladder carcinoma (UBC) remains elusive. Here, single-cell RNA sequencing (scRNA-seq) were performed on total 30,905 T cells derived from peripheral blood, adjacent normal and tumor tissues from two UBC patients. We identified 18 distinct T cell subsets based on molecular profiles and functional properties. Specifically, exhausted T (TEx) cells, exhausted NKT (NKTEx) cells, Ki67+ T cells and B cell-like T (B-T) cells were exclusively enriched in UBC. Additionally, the gene signatures of TEx, NKTEx, Ki67+ T and B-T cells were significantly associated with poor survival in patients with BC and various tumor types. Finally, IKZF3 and TRGC2 are the potential biomarkers of TEx cells. Overall, our study demonstrated an exhausted context of T cells in UBC, which layed a theoretical foundation for the development of effective tumor immunotherapies.© 2023. Springer Nature Limited.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

最新[2023]版：

大类 | 2 区综合性期刊

小类 | 2 区综合性期刊

JCR分区：

出版当年[2021]版：

Q2 MULTIDISCIPLINARY SCIENCES

最新[2023]版：

Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 3.8 最新[2023版] 4.3 最新五年平均 4.997 出版当年[2021版] 5.516 出版当年五年平均 4.38 出版前一年[2020版] 4.6 出版后一年[2022版]

第一作者：

第一作者机构： [1]College of Life Science and Technology, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China [2]College of Life Science and Technology, Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin of Xinjiang Production and Construction Corps, Tarim University, Alar 843300, Xinjiang, China

共同第一作者：

通讯作者：

通讯机构： [1]College of Life Science and Technology, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China [2]College of Life Science and Technology, Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin of Xinjiang Production and Construction Corps, Tarim University, Alar 843300, Xinjiang, China

推荐引用方式(GB/T 7714)：

APA：

MLA：